Immunogenicity and safety of different injection routes and schedules of IC41, a Hepatitis C virus (HCV) peptide vaccine

Vaccine

Volumn 28, Issue 12, 2010, Pages 2397-2407

  Firbas, Christa ^a   Boehm, Thomas ^c   Buerger, Vera ^c   Schuller, Elisabeth ^c   Sabarth, Nicolas ^b   Jilma, Bernd ^a   Klade, Christoph S ^c  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b BAXTER BIOSCIENCE   (Austria)

^c INTERCELL AG   (Austria)

Author keywords

Healthy subjects; Hepatitis C vaccine; IC41

Indexed keywords

EPITOPE; GAMMA INTERFERON; HEPATITIS C VACCINE; HLA A ANTIGEN; IC 41; IMIQUIMOD; PEPTIDE VACCINE; THYMIDINE; UNCLASSIFIED DRUG;

ADULT; ANOREXIA; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ASSAY; CELLULAR IMMUNITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; ENZYME LINKED IMMUNOSPOT ASSAY; EYELID EDEMA; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IMMUNITY; IMMUNOGENICITY; INJECTION SITE EDEMA; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE INFECTION; INJECTION SITE INFLAMMATION; INJECTION SITE NECROSIS; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE REACTION; INJECTION SITE SWELLING; LYMPHOCYTE PROLIFERATION; MALE; NAUSEA; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKIN TUBERCULOSIS; URTICARIA;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; AMINOQUINOLINES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; FEMALE; HEPACIVIRUS; HUMANS; IMMUNIZATION SCHEDULE; IMMUNIZATION, SECONDARY; INJECTIONS, INTRADERMAL; INJECTIONS, SUBCUTANEOUS; INTERFERON-GAMMA; MALE; MIDDLE AGED; VACCINES, SUBUNIT; VIRAL HEPATITIS VACCINES; YOUNG ADULT;

EID: 77549085401     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.12.072     Document Type: Article

References (45)

1. Wasley A., and Alter M.J. Epidemiology of hepatitis C: geographic differences and temporal trends. Semin Liver Dis 20 1 (2000) 1-16
2. Shepard C.W., Finelli L., and Alter M.J. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 5 9 (2005) 558-567
3. World Health Organization. Hepatitis C-global surveillance update. Wkly Epidemiol Rec 75 (2000) 17-28
4. Management of hepatitis C: 2002. Consensus Development Conference statement, National Institutes of Health Consensus Development Conference (2002 June 10-12). NIH Consensus Development Program. Available online: http://consensus.nih.gov/2002/2002HepatitisC2002116html.htm (accessed September 2009).
5. Cerny A., and Chisari F.V. Pathogenesis of chronic hepatitis C: immunological features of hepatic injury and viral persistence. Hepatology 30 3 (1999) 595-601
6. Lohmann V., Koch J.O., and Bartenschlager R. Processing pathways of the hepatitis C virus proteins. J Hepatol 24 2 Suppl. (1996) 11-19
7. Purcell R. The hepatitis C virus: overview. Hepatology 26 3 Suppl. 1 (1997) 11S-14S
8. Amoroso P., Rapicetta M., Tosti M.E., Mele A., Spada E., Buonocore S., et al. Correlation between virus genotype and chronicity rate in acute hepatitis C. J Hepatol 28 6 (1998) 939-944
9. Brechot C., and Hepatitis. C virus: molecular biology and genetic variability. Dig Dis Sci 41 12 Suppl. (1996) 6S-21S
10. Shin H., and Wherry E.J. CD8 T cell dysfunction during chronic viral infection. Curr Opin Immunol 19 4 (2007) 408-415
11. Farci P., Alter H.J., Wong D.C., Miller R.H., Govindarajan S., Engle R., et al. Prevention of hepatitis C virus infection in chimpanzees after antibody-mediated in vitro neutralization. Proc Natl Acad Sci U S A 91 16 (1994) 7792-7796
12. Prince A.M. Challenges for development of hepatitis C virus vaccines. FEMS Microbiol Rev 14 3 (1994) 273-277
13. Stoll-Keller F., Barth H., Fafi-Kremer S., Zeisel M.B., and Baumert T.F. Development of hepatitis C virus vaccines: challenges and progress. Expert Rev Vaccines 8 3 (2009) 333-345
14. Bukh J., Miller R.H., and Purcell R.H. Genetic heterogeneity of hepatitis C virus: quasispecies and genotypes. Semin Liver Dis 15 1 (1995) 41-63
15. Farci P., Shimoda A., Wong D., Cabezon T., De Gioannis D., Strazzera A., et al. Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein. Proc Natl Acad Sci U S A 93 26 (1996) 15394-15399
16. Strickland G.T., El-Kamary S.S., Klenerman P., and Nicosia A. Hepatitis C vaccine: supply and demand. Lancet Infect Dis 8 6 (2008) 379-386
17. Firbas C., Jilma B., Tauber E., Buerger V., Jelovcan S., Lingnau K., et al. Immunogenicity and safety of a novel therapeutic hepatitis C virus (HCV) peptide vaccine: a randomized, placebo controlled trial for dose optimization in 128 healthy subjects. Vaccine 24 20 (2006) 4343-4353
18. Klade C.S., Wedemeyer H., Berg T., Hinrichsen H., Cholewinska G., Zeuzem S., et al. Therapeutic vaccination of chronic hepatitis C nonresponder patients with the peptide vaccine IC41. Gastroenterology 134 5 (2008) 1385-1395
19. Schlaphoff V., Klade C.S., Jilma B., Jelovcan S.B., Cornberg M., Tauber E., et al. Functional and phenotypic characterization of peptide-vaccine-induced HCV-specific CD8+ T cells in healthy individuals and chronic hepatitis C patients. Vaccine 25 37-38 (2007) 6793-6806
20. Diepolder H.M., Zachoval R., Hoffmann R.M., Jung M.C., Gerlach T., and Pape G.R. The role of hepatitis C virus specific CD4+ T lymphocytes in acute and chronic hepatitis C. J Mol Med 74 10 (1996) 583-588
21. Missale G., Bertoni R., Lamonaca V., Valli A., Massari M., Mori C., et al. Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response. J Clin Invest 98 3 (1996) 706-714
22. Keilholz U., Weber J., Finke J.H., Gabrilovich D.I., Kast W.M., Disis M.L., et al. Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy. J Immunother 25 2 (2002) 97-138
23. Lalvani A., Brookes R., Hambleton S., Britton W.J., Hill A.V., and McMichael A.J. Rapid effector function in CD8+ memory T cells. J Exp Med 186 6 (1997) 859-865
24. FDA Guidance for Industry: toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trials. September 2007.
25. Hoofnagle J.H. A step forward in therapy for hepatitis C. N Engl J Med 360 18 (2009) 1899-1901
26. Leroux-Roels G., Leroux-Roels G., Depla E., Hulstaert F., Tobback L., Dincq S., et al. A candidate vaccine based on the hepatitis C E1 protein: tolerability and immunogenicity in healthy volunteers. Vaccine 22 23-24 (2004) 3080-3086
27. Nevens F., Roskams T., Van Vlierberghe H., Horsmans Y., Sprengers D., Elewaut A., et al. A pilot study of therapeutic vaccination with envelope protein E1 in 35 patients with chronic hepatitis C. Hepatology 38 5 (2003 Nov) 1289-1296
28. Habersetzer F., Zarski J.P., and Leroy V. A novel vectorized HCV Therapeutic Vaccine (Tg4040): results of a Phase I study in naive patients chronically infected by HCV. 44th annual meeting of the European Association for the Study of the Liver (EASL 2009). Copenhagen, Denmark, April 22-26 (2009)
29. Yutani S., Komatsu N., Shichijo S., Yoshida K., Takedatsu H., Itou M., et al. Phase I clinical study of a peptide vaccination for hepatitis C virus-infected patients with different human leukocyte antigen-class I-A alleles. Cancer Sci June (2009) [Epub ahead of print]
30. Lawitz E.J., Boyer T.D., and Everson G.T. GI-5005 Immunotherapy plus Peg-IFN/Ribavirin versus Peg-Ifn/Ribavirin in genotype 1 chronic HCV subjects; preliminary phase 2 EVR analyses. 44th annual meeting of the European Association for the Study of the Liver (EASL 2009). Copenhagen, Denmark, April 22-26 (2009)
31. Wedemeyer H., Schuller E., Schlaphoff V., Stauber R.E., Wiegand J., Schiefke I., et al. Therapeutic vaccine IC41 as late add-on to standard treatment in patients with chronic hepatitis C. Vaccine 27 37 (2009) 5142-5151
32. Sallberg M.M., Frelin L., and Diepolder H. A first clinical trial of therapeutic vaccination using naked DNA delivered by in vivo electroporation shows antiviral effects in patients with chronic hepatitis C. 44th annual meeting of the European Association for the Study of the Liver (EASL 2009). Copenhagen, Denmark, April 22-26 (2009)
33. Novak N., Yu C.F., Bieber T., and Allam J.P. Toll-like receptor 7 agonists and skin. Drug News Perspect 21 3 (2008) 158-165
34. Schiller M., Metze D., Luger T.A., Grabbe S., and Gunzer M. Immune response modifiers-mode of action. Exp Dermatol 15 5 (2006) 331-341
35. Adams S., O'Neill D.W., Nonaka D., Hardin E., Chiriboga L., Siu K., et al. Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant. J Immunol 181 1 (2008) 776-784
36. Shackleton M., Davis I.D., Hopkins W., Jackson H., Dimopoulos N., Tai T., et al. The impact of imiquimod, a Toll-like receptor-7 ligand (TLR7L), on the immunogenicity of melanoma peptide vaccination with adjuvant Flt3 ligand. Cancer Immun 4 (2004) 9-20
37. Kenney R.T., Frech S.A., Muenz L.R., Villar C.P., and Glenn G.M. Dose sparing with intradermal injection of influenza vaccine. N Engl J Med 351 22 (2004) 2295-2301
38. Redfield R.R., Innis B.L., Scott R.M., Cannon H.G., and Bancroft W.H. Clinical evaluation of low-dose intradermally administered hepatitis B virus vaccine. A cost reduction strategy. JAMA 254 December (22) (1985) 3203-3206
39. Briggs D.J., Banzhoff A., Nicolay U., Sirikwin S., Dumavibhat B., Tongswas S., et al. Antibody response of patients after postexposure rabies vaccination with small intradermal doses of purified chick embryo cell vaccine or purified Vero cell rabies vaccine. Bull World Health Organ 78 5 (2000) 693-698
40. Wedemeyer H., Mizukoshi E., Davis A.R., Bennink J.R., and Rehermann B. Cross-reactivity between hepatitis C virus and Influenza A virus determinant-specific cytotoxic T cells. J Virol 75 23 (2001) 11392-11400
41. Miller R.L., Meng T.C., and Tomai M.A. The antiviral activity of Toll-like receptor 7 and 7/8 agonists. Drug News Perspect 21 2 (2008) 69-87
42. Dowd K.A., Hershow R.C., Yawetz S., Larussa P., Diaz C., Landesman S.H., et al. Maternal neutralizing antibody and transmission of hepatitis C virus to infants. J Infect Dis 198 11 (2008) 1651-1655
43. Pestka J.M., Zeisel M.B., Bläser E., Schürmann P., Bartosch B., and Cosset F.L. et al Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C. Proc Natl Acad Sci U S A 104 14 (2007) 6025-6030
44. Lavillette D., Tarr A.W., Voisset C., Donot P., Bartosch B., Bain C., et al. Characterization of host-range and cell entry properties of the major genotypes and subtypes of hepatitis C virus. Hepatology 41 2 (2005) 265-274
45. Radziewicz H., Dunham R.M., and Grakoui A. PD-1 tempers Tregs in chronic HCV infection. J Clin Invest 119 3 (2009) 450-453